Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/Day for the Treatment of Active Ulcerative Colitis

NCT01903252 is registered in ClinicalTrials.gov with Tillotts Pharma AG as lead sponsor.

NCT NCT01903252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01903252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/Day for the Treatment of Active Ulcerative Colitis
Lead sponsor
Tillotts Pharma AG
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2013
Completion date
November 30, 2016
Enrollment
817 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ulcerative colitis